AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
81 hedge funds and large institutions have $61.9M invested in AVEO Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 9 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less funds holding
Funds holding: 82 → 81 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
21% less capital invested
Capital invested by funds: $78.5M → $61.9M (-$16.6M)
96% less call options, than puts
Call options by funds: $7K | Put options by funds: $188K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.15M |
| 2 |
D.E. Shaw & Co
New York
|
+$952K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$839K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$528K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$516K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.83M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.62M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.1M |
| 5 |
ARC
Absolute Return Capital
Boston,
Massachusetts
|
-$907K |
AVEO Hedge Fund Activity: Q3 2013 in Review
81 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2013, worth a combined $61.9M — down 21% from $78.5M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AVEO and 8 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 31 added.
The largest buyer was TFS Capital, adding an estimated $1.15M. The largest seller was Credit Suisse, cutting an estimated $1.83M.
- 81 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2013, down from 82 in Q2 2013.
- Funds reported $61.9M of AVEO Pharmaceuticals, Inc. stock for Q3 2013, down 21% quarter-over-quarter.
- 8 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2013 and 9 closed out, a net change of -1 holder.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2013 was TFS Capital, an estimated $1.15M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2013 was Credit Suisse, an estimated $1.83M sold.
Based on aggregated 13F filings for Q3 2013.